Highest-materiality recent filing
Precipio Q2 2026 revenue record $7.0M, positive adjusted EBITDA $0.4M
Revenue $7.0M, up 22% YoY from $5.7M; pathology $6.1M, product $0.9M.
Precipio reports 30% revenue growth to $24M in 2025; positive EBITDA and cash flow
Revenue grew 30% YoY to $24.0M in FY2025; Q4 revenue up 23% YoY to $6.7M.
Precipio Q1 revenue up 43% to $4.9M; adjusted EBITDA loss narrows 92% to $108K
Revenue $4.9M, +43% YoY; overall gross margin improved to 43% from 27%.
Precipio achieves two of three 2023 goals; revenue up ~50% YoY, cash burn cut 60%
Pathology division hit $14M annualized revenue in Q3, meeting target #1; product target lowered to $6M.
Nasdaq confirmed compliance on Oct 6, 2023, based on closing bid prices from Sep 22 to Oct 5, 2023.
Precipio effects 1-for-20 reverse stock split to regain Nasdaq compliance
Reverse split 1-for-20 effective Sept 21, 2023; split-adjusted trading starts Sept 22.
Precipio enters ATM equity offering agreement for up to $5.8M with A.G.P.
Entered Sales Agreement with A.G.P./Alliance Global Partners for at-the-market offering of common stock up to $5.8M.
Precipio receives Nasdaq notice of non-compliance with $1.00 bid price rule
Closing bid price per share below $1.00 for 30 consecutive business days as of October 28, 2022.
Precipio enters distribution agreement with Fisher Healthcare for HemeScreen assays
Precipio (PRPO) entered a distribution agreement with Fisher Healthcare (Thermo Fisher Scientific) for HemeScreen assays.
Precipio reports preliminary 2021 revenue of $8.9M, up 45% YoY; Q4 revenue $2.4M up 25%
Preliminary unaudited 2021 revenue $8.9M, up $2.8M (45%) from 2020.
the Board appointed Ms. Christina Valauri to fill the vacancy left by Mr. Fisher’s resignation and to serve as a class II director of the Company
the Board of Directors (the “Board”) of Precipio, Inc. (the “Company”) accepted the resignation of Douglas Fisher as a member of the Board
Management together with the Board of Directors of the Company has promoted and appointed Matthew Gage (age 55), currently the Company’s Director of Financial Reporting and Analysis, as the Company’s Interim Chief Financial Officer effective March 21, 2022.
announced the retirement of its Chief Financial Officer, Carl Iberger, (age 69) effective immediately due to personal family reasons.
Max materiality 0.85 · Median 0.30 · Most common event other_material